TEM News

eyonis® LCS démarre sa commercialisation aux États‑Unis après l’obtention de l’autorisation FDA ; Oran Muduroglu est nommé Président de Median eyonis Inc.

FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis ® LCS Software as a Medical Device in the United States

Median Technologies annonce sa collaboration avec Tempus pour développer l’accès au logiciel dispositif médical eyonis ® LCS aux États‑Unis

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers